<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>Treatment of Current (Active) Disease Therapy </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>
<div class="uk-container">
    <h4>List of Subchapters</h4>
    
    <ul class="uk-list uk-list-hyphen">
        <li><a href="5_treatment_of_current_(active)_disease_therapy__a__considerations.html">Considerations</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__b__standard_therapy_for_current_(active)_disease.html" >Standard Therapy for Current (active) Disease</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__c__special_clinical_situations.html">Special Clinical Situations</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__d__drug_resistance.html">Drug Resistance</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__e__monitoring_patients_on_therapy_for_response_and_adverse_events.html">Monitoring Patients on Therapy for Response and Adverse Events</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__f__tb_and_hiv.html">TB and HIV</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__g__antiretroviral_therapy_(art)_and_treatment_of_persons.html">Antiretroviral Therapy (ART) and Treatment of Seropositive Patients with Active Tuberculosis</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__h__immune_reconstitution_inflammatory_syndrome.html">Immune Reconstitution Inflammatory Syndrome (IRIS) Associated with Initiation of Antiretroviral Therapy During the Course of TB Therapy</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__i__treatment_of_extrapulmonary_tb.html">Treatment of Extrapulmonary TB</a></li>
        <li><a href="5_treatment_of_current_(active)_disease_therapy__j__adjunctive_use_of_corticosteroid_therapy.html">Adjunctive Use of Corticosteroid Therapy</a></li>
    </ul>
    <h4>List of charts</h4>
    <ul class="uk-list uk-list-hyphen">
        <li><a href="table_7_recommended_regimens_for_treatment_of_adults_and_children_with_drug_susceptible_tb_pulmonary_tb.html">Table 7. Recommended Regimens for treatment of adults and children with Drug-Susceptible TB Pulmonary TB</a></li>
        <li><a href="table_8_first-line_tb_drugs_dosing_for_adults_(ages_16_and_over)_directly_observed_therapy_(dot)_is_mandatory.html">Table 8. First-Line TB Drugs: Dosing for Adults (ages 16 and over) Directly Observed Therapy (DOT) is mandatory</a></li>
        <li><a href="table_9_pediatric_dosage_isoniazid_in_children_(birth_to_15_years).html">Table 9. Pediatric Dosage - Isoniazid in Children (birth to 15 years)</a></li>
        <li><a href="table_10_pediatric_dosages_rifampin_in_children_(birth_to_15_years).html">Table 10. Pediatric Dosage - Rifampin in Children (birth to 15 years)</a></li>
        <li><a href="table_11_pediatric_dosages_ethambutol_in_children_(birth_to_15_years).html">Table 11. Pediatric Dosage - Ethambutol in Children (birth to 15 years)</a></li>
        <li><a href="table_12_pediatric_dosages_pyrazinamide_in_children_(birth_to_15_years).html">Table 12. Pediatric Dosage - Pyrazimanide in Children (birth to 15 years)</a></li>
        <li><a href="table_13_antituberculosis_antibiotics_in_adult_patients_with_renal_impairment.html">Table 13. Antituberculosis Antibiotics in adults patients with Renal Impairment</a></li>
        <li><a href="table_14_antituberculosis_medications_which_may_be_used_for_patients_who_have_contraindications_to_or_intolerance.html">Table 14. Antituberculosis medications which may be used for patients who have contraindications to or intolerance of first line agents or who require IV therapy during acute or critical illness</a></li>
        <li><a href="table_15_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated.html">Table 15. Clinical Situations for which standard therapy cannot be given or is not well- tolerated or may not be effective: Potential Alternative Regimens (Dosing and/or Drugs)</a></li>
        <li><a href="table_16_when_to_start_hiv_therapy.html">Table 16. When to start HIV therapy</a></li>
        <li><a href="table_17_what_to_start_choice_of_tb_therapy_and_antiretroviral_therapy_(art)_when)treating_co-infected_patients.html">Table 17. What to start: Choice of TB therapy and Antiretroviral Therapy (ART) when treating co-infected patients</a></li>
        <li><a href="table_18_dosage_adjustments_for_art_and_rifamycins_when_used_in_combination.html">Table 18. Dosage Adjustments for ART and Rifamycins when used in Combination</a></li>
        <li><a href="table_19_guidelines_for_treatment_of_extrapulmonary_tuberculosis.html">Table 19. Guidelines for Treatment of Extrapulmonary* Tuberculosis: Length of therapy and Adjunctive Use of Corticosteroids</a></li>
    </ul>
    <h4> List of Figures </h4>
    <ul class="uk-list uk-list-hyphen">
        <li><a href="fig1_factors_to_be_considered.html">Figure 1. Factors to be considered in deciding to initiate treatment empirically for active tuberculosis (TB) (prior to microbiologic confirmation)</a></li>
    </ul>
    
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
</html>
